Health Care

It was 8 o'clock on a weeknight and Brooklyn resident Sarah Sheehan was reeling from a painful earache.

A top U.S. auto safety regulator says that Fiat Chrysler failed to provide timely and accurate recall information to her agency and that customers also have problems getting accurate information.

The chief U.S. auto safety regulator says Fiat Chrysler will face sanctions for violating safety laws in multiple recalls.

The liquid is dark red, a mixture of fat and blood, and Dr. Mark Berman pumps it out of the patient's backside.

New technologies account for one way that the government is tracking a life-threatening outbreak of listeria linked to Blue Bell ice cream products.

Attachments for a hand vacuum are being recalled because of a defective interior fan that can break out of the housing unit.

Google's ambitious health startup is teaming up with biotechnology drugmaker AbbVie in a $500 million joint venture that will try to develop new ways to treat cancer and other diseases such as Alzheimer's.

Rhode Island lawmakers are considering raising the state's minimum wage again.

Shares of biotechnology companies are tumbling over price-control concerns following Democratic presidential frontrunner Hillary Clinton's statement that she will release a plan to address "price gouging" in the industry.

Analysts say they expect more tie-ups are coming in the generic drug industry in the wake of Teva's mammoth deal for the generic drug business of Allergan.

Shares of Synergy Pharmaceuticals jumped 47 percent before Wednesday's opening bell on encouraging, late-state study results for its constipation drug.

Shares of Universal Health Services fell Wednesday after the company disclosed that the U.S. government expanded its fraudulent billing investigation to include the hospital operator as a corporate entity.

Shares of ImmunoGen jumped 23 percent in premarket trading Monday after the biotechnology company signed a licensing deal with Japan's Takeda Pharmaceutical Co.

Biogen Idec released much anticipated results from a study of a potential Alzheimer's disease treatment on Friday, showing that it slowed cognitive decline in some patients.

AbbVie Inc. says it is buying leukemia drugmaker Pharmacyclics for $21 billion.

The biggest obstacle for Coca-Cola and Pepsi these days isn't tied to taste tests, the declining popularity of sugary drinks or even their century-long rivalry.

The biggest obstacle for Coca-Cola and Pepsi these days isn't tied to taste tests, the declining popularity of sugary drinks or even their century-long rivalry.

Shares of Achillion Pharmaceuticals Inc. jumped Monday morning after the drug developer said a small group of patients who took its experimental hepatitis C treatment combination remained free of the liver-destroying virus three months after they stopped taking doses.

Shares of Gilead Sciences Inc. dropped Wednesday after the drugmaker's executives discussed pricing discounts and competition facing its blockbuster hepatitis C drugs.

A 30 percent swing in a blink of an eye is not uncommon in the stock market.